+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Becker Muscular Dystropy Market - Global Forecast 2026-2032- Product Image
Becker Muscular Dystropy Market - Global Forecast 2026-2032- Product Image
Sale

Becker Muscular Dystropy Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6280574
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Becker Muscular Dystrophy: Executive Summary

Becker muscular dystrophy (BMD) is an X-linked genetic neuromuscular disorder caused by variants in the DMD gene that allow production of partially functional dystrophin. Compared with Duchenne muscular dystrophy, BMD generally has later onset and a more variable course, although substantial disability and life-threatening cardiac or respiratory complications can occur. Clinical priorities include timely diagnosis, multidisciplinary monitoring, preservation of mobility, cardiac surveillance, respiratory care, rehabilitation, and psychosocial support.

Earlier Recognition and Integrated Care Are Reshaping BMD Management

The BMD care landscape is shifting from symptom-led treatment toward coordinated, longitudinal management. Genetic confirmation, neuromuscular specialist assessment, physical and occupational therapy, cardiac imaging, rhythm surveillance, respiratory evaluation, orthopedic review, and patient-centered support increasingly need to be connected across the care pathway. Earlier recognition of cardiomyopathy risk, informed reproductive counseling, and individualized activity guidance are especially important because disease expression varies widely among affected individuals and families.

Artificial Intelligence Is Strengthening Diagnosis, Monitoring, and Research

Artificial intelligence can support BMD care by identifying patterns in genetic data, imaging, electrodiagnostic results, electronic health records, and longitudinal functional assessments. Potential applications include variant interpretation, automated analysis of cardiac and muscle imaging, prediction of clinical deterioration, and improved selection of participants for research. These tools remain assistive rather than definitive: validation in diverse populations, explainability, privacy protection, clinician oversight, and management of false-positive or false-negative results are essential before routine adoption.

Regional Insights: Access and Infrastructure Vary Across Six Major Regions

North America generally benefits from established neuromuscular networks, genetic testing capacity, and specialized cardiac and respiratory services, though insurance coverage and geographic distance can affect continuity. Europe has strong specialist centers and collaborative rare-disease infrastructure, but access and reimbursement differ among countries. Asia-Pacific combines advanced services in some health systems with major access gaps elsewhere. Latin America faces uneven availability of genetic confirmation, rehabilitation, and specialist follow-up. The Middle East is expanding specialist and genomic capabilities, while referral concentration can remain a barrier. Africa continues to face limited diagnostic infrastructure, specialist shortages, and substantial under-recognition, making clinician education, referral pathways, and affordable testing important priorities.

Group Insights: Policy Blocs Can Improve Rare-Disease Coordination

ASEAN cooperation can support shared diagnostic pathways, clinician training, and cross-border referral for complex neuromuscular disorders. BRICS members have an opportunity to strengthen genomic services, registry interoperability, and research collaboration while addressing uneven access within and between countries. The European Union can advance coordinated standards, data sharing, and cross-border care through existing rare-disease mechanisms. G7 countries can help establish evidence, quality, and patient-safety practices for emerging diagnostics and digital tools. GCC states can build regional centers of expertise and coordinated genetic counseling. NATO members may benefit from interoperable rehabilitation, telemedicine, and continuity-of-care planning for mobile populations, while maintaining civilian clinical governance.

Country Insights: National Priorities Differ Across the BMD Care Pathway

Australia can use centralized rare-disease networks and telehealth to connect patients with specialist services across long distances. Brazil and Mexico would benefit from stronger referral systems, broader access to molecular diagnosis, and consistent rehabilitation and cardiac follow-up. Canada and the United States have substantial specialist capacity but must address regional disparities, coverage complexity, and transition from pediatric to adult care. China and India face large population-level needs alongside rapid development of genomic and specialty infrastructure. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established neuromuscular expertise, with ongoing priorities including equitable access, coordinated adult services, and sustainable multidisciplinary monitoring. Russia faces the need to maintain diagnostic, rehabilitation, and specialist continuity across geographically dispersed communities.

Action Priorities for Leaders: Diagnose Earlier and Coordinate Long-Term Care

Industry and health-system leaders should invest in clinician education that recognizes variable BMD presentations, expand access to confirmatory genetic testing with counseling, and create referral pathways linking neuromuscular, cardiac, respiratory, rehabilitation, and psychosocial services. Care models should include regular cardiac assessment, individualized exercise and mobility planning, respiratory review when clinically indicated, and structured transition to adult care. Leaders should also support interoperable registries, patient-reported outcomes, ethical use of AI, transparent evidence generation, and partnerships with patient organizations. Programs should measure diagnostic delay, follow-up completion, functional outcomes, quality of life, and equitable access across geography and socioeconomic status.

Research Methodology: Evidence-Based Synthesis of BMD Care Priorities

This executive summary applies a disease-centered synthesis of established clinical, genetic, public-health, and health-system principles relevant to Becker muscular dystrophy. It distinguishes broadly recognized care priorities from emerging applications such as artificial intelligence and avoids unsupported quantitative claims. Regional, group, and country observations are framed as contextual considerations rather than estimates or forecasts. Interpretation should be supplemented with current clinical guidelines, national policies, regulatory requirements, peer-reviewed evidence, and consultation with neuromuscular specialists and affected communities.

Conclusion: Coordinated, Equitable Monitoring Is Central to Better BMD Outcomes

BMD requires lifelong, individualized management because functional progression and cardiac or respiratory involvement can differ substantially among patients. The strongest strategic opportunity is to connect earlier genetic diagnosis with dependable multidisciplinary follow-up and equitable access to specialist care. Advances in digital health, registries, imaging, and AI may improve decision support, but they should complement-rather than replace-clinical expertise, patient preferences, and robust safeguards. Sustainable progress depends on collaboration among health systems, researchers, clinicians, families, and patient organizations.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Becker Muscular Dystropy Market, by Product Type
7.1. Introduction
7.2. Cell Therapy
7.3. Diagnostics
7.3.1. Biomarker Testing
7.3.2. Genetic Testing
7.3.3. Muscle Imaging
7.4. Gene Therapy
7.4.1. AAV-Based
7.4.2. Non-Viral
7.5. Pharmacological Therapies
7.5.1. Antisense Oligonucleotides
7.5.2. Corticosteroids
7.5.3. Enzyme Modulators
7.5.4. Small Molecule Drugs
7.6. Protein Replacement
7.7. Supportive Care
7.7.1. Cardiovascular Management
7.7.2. Orthotics
7.7.3. Physical Therapy
7.7.4. Respiratory Support
8. Becker Muscular Dystropy Market, by Therapy Approach
8.1. Introduction
8.2. Disease Modifying
8.2.1. CRISPR/Cas Genome Editing
8.2.2. Exon Skipping
8.2.3. Gene Replacement
8.2.4. Nonsense Mutation Read-Through
8.3. Regenerative Therapy
8.4. Symptomatic Management
9. Becker Muscular Dystropy Market, by Drug Class
9.1. Introduction
9.2. Antisense Oligonucleotides
9.3. Cardioprotective Agents
9.4. Gene Therapies
9.5. Small Molecules
9.6. Steroids
10. Becker Muscular Dystropy Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intrathecal
10.4. Oral
10.5. Subcutaneous
11. Becker Muscular Dystropy Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Rehabilitation Centers
11.5. Specialty Clinics
12. Becker Muscular Dystropy Market, by Distribution Channel
12.1. Introduction
12.2. Direct To Patient
12.3. Hospital Pharmacies
12.4. Retail Pharmacies
12.5. Specialty Pharmacies
13. Becker Muscular Dystropy Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Becker Muscular Dystropy Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Becker Muscular Dystropy Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Astellas Pharma Inc.
17.2. BioMarin Pharmaceutical Inc.
17.3. Capricor Therapeutics, Inc.
17.4. Dyne Therapeutics, Inc.
17.5. Edgewise Therapeutics, Inc.
17.6. Epirium Bio, Inc.
17.7. Exonics Therapeutics, Inc.
17.8. Immuno Forge Co., Ltd.
17.9. Ionis Pharmaceuticals, Inc.
17.10. Italfarmaco S.p.A.
17.11. Novartis AG
17.12. Pfizer Inc.
17.13. PTC Therapeutics, Inc.
17.14. ReveraGen BioPharma, Inc.
17.15. Roche Holding AG
17.16. Santhera Pharmaceuticals Holding AG
17.17. Sarepta Therapeutics, Inc.
17.18. Solid Biosciences, Inc.
17.19. Ultragenyx Pharmaceutical Inc
17.20. Wave Life Sciences Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Becker Muscular Dystropy Market, Years Considered for the Study
FIGURE 2. Global Becker Muscular Dystropy Market, Research Design
FIGURE 3. Global Becker Muscular Dystropy Market, Research Framework
FIGURE 4. Global Becker Muscular Dystropy Market, Data Triangulation
FIGURE 5. Global Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Becker Muscular Dystropy Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Becker Muscular Dystropy Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Becker Muscular Dystropy Market Size, by Therapy Approach, 2025 vs 2032 (%)
FIGURE 9. Global Becker Muscular Dystropy Market Size, by Therapy Approach, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Becker Muscular Dystropy Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 11. Global Becker Muscular Dystropy Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Becker Muscular Dystropy Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 13. Global Becker Muscular Dystropy Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Becker Muscular Dystropy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Becker Muscular Dystropy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Becker Muscular Dystropy Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Becker Muscular Dystropy Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Becker Muscular Dystropy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Becker Muscular Dystropy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Becker Muscular Dystropy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Becker Muscular Dystropy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Becker Muscular Dystropy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Becker Muscular Dystropy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Becker Muscular Dystropy Market Segmentation & Coverage
TABLE 2. Global Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
TABLE 3. Global Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Biomarker Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Biomarker Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Biomarker Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Genetic Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Genetic Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Genetic Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Muscle Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Muscle Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Muscle Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global AAV-Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global AAV-Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global AAV-Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Non-Viral Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Non-Viral Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Non-Viral Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Pharmacological Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Pharmacological Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Pharmacological Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Antisense Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Antisense Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Antisense Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Enzyme Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Enzyme Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Enzyme Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Small Molecule Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Small Molecule Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Small Molecule Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Protein Replacement Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Protein Replacement Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Protein Replacement Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Supportive Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Supportive Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Supportive Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Cardiovascular Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Cardiovascular Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Cardiovascular Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Orthotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Orthotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Orthotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Physical Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Physical Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Physical Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Respiratory Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Respiratory Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Respiratory Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 62. Global Disease Modifying Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Disease Modifying Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Disease Modifying Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global CRISPR/Cas Genome Editing Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global CRISPR/Cas Genome Editing Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global CRISPR/Cas Genome Editing Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Exon Skipping Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Exon Skipping Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Exon Skipping Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Gene Replacement Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Gene Replacement Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Gene Replacement Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Nonsense Mutation Read-Through Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Nonsense Mutation Read-Through Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Nonsense Mutation Read-Through Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Regenerative Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Regenerative Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Regenerative Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Symptomatic Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Symptomatic Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Symptomatic Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 84. Global Antisense Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Antisense Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Antisense Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Cardioprotective Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Cardioprotective Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Cardioprotective Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Gene Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Steroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Steroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Steroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 100. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Rehabilitation Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Rehabilitation Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Rehabilitation Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. Global Direct To Patient Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Global Direct To Patient Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. Global Direct To Patient Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 132. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 135. Global Specialty Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Global Specialty Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. Global Specialty Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 138. Global Becker Muscular Dystropy Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific Becker Muscular Dystropy Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 143. Asia-Pacific Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 144. Asia-Pacific Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 145. Asia-Pacific Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 146. Asia-Pacific Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 147. Asia-Pacific Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 148. Asia-Pacific Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. Asia-Pacific Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Asia-Pacific Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. North America Becker Muscular Dystropy Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. North America Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 153. North America Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 154. North America Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 155. North America Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 156. North America Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 157. North America Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 158. North America Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 159. North America Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 160. North America Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. North America Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. North America Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Latin America Becker Muscular Dystropy Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Latin America Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 165. Latin America Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 166. Latin America Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 167. Latin America Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 168. Latin America Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 169. Latin America Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 170. Latin America Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 171. Latin America Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 172. Latin America Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. Latin America Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. Latin America Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Europe Becker Muscular Dystropy Market Size, by Region, 2017-2032 (USD Million)
TABLE 176. Europe Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. Europe Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 178. Europe Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 179. Europe Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 180. Europe Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 181. Europe Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 182. Europe Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 183. Europe Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 184. Europe Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 185. Europe Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 186. Europe Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. Middle East Becker Muscular Dystropy Market Size, by Region, 2017-2032 (USD Million)
TABLE 188. Middle East Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 189. Middle East Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 190. Middle East Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 191. Middle East Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 192. Middle East Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 193. Middle East Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 194. Middle East Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 195. Middle East Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 196. Middle East Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 197. Middle East Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. Middle East Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. Africa Becker Muscular Dystropy Market Size, by Region, 2017-2032 (USD Million)
TABLE 200. Africa Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. Africa Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 202. Africa Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 203. Africa Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 204. Africa Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 205. Africa Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 206. Africa Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 207. Africa Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 208. Africa Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. Africa Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 210. Africa Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 211. Global Becker Muscular Dystropy Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. ASEAN Becker Muscular Dystropy Market Size, by Group, 2017-2032 (USD Million)
TABLE 213. ASEAN Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 214. ASEAN Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 215. ASEAN Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 216. ASEAN Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 217. ASEAN Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 218. ASEAN Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 219. ASEAN Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 220. ASEAN Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 221. ASEAN Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 222. ASEAN Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. ASEAN Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. GCC Becker Muscular Dystropy Market Size, by Group, 2017-2032 (USD Million)
TABLE 225. GCC Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 226. GCC Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 227. GCC Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 228. GCC Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 229. GCC Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 230. GCC Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 231. GCC Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 232. GCC Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 233. GCC Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 234. GCC Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. GCC Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. European Union Becker Muscular Dystropy Market Size, by Group, 2017-2032 (USD Million)
TABLE 237. European Union Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 238. European Union Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 239. European Union Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 240. European Union Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 241. European Union Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 242. European Union Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 243. European Union Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 244. European Union Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 245. European Union Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 246. European Union Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. European Union Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. BRICS Becker Muscular Dystropy Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. BRICS Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 250. BRICS Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 251. BRICS Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 252. BRICS Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 253. BRICS Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 254. BRICS Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 255. BRICS Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 256. BRICS Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 257. BRICS Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 258. BRICS Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. BRICS Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. G7 Becker Muscular Dystropy Market Size, by Group, 2017-2032 (USD Million)
TABLE 261. G7 Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 262. G7 Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 263. G7 Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 264. G7 Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 265. G7 Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 266. G7 Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 267. G7 Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 268. G7 Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 269. G7 Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 270. G7 Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. G7 Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 272. NATO Becker Muscular Dystropy Market Size, by Group, 2017-2032 (USD Million)
TABLE 273. NATO Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 274. NATO Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 275. NATO Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 276. NATO Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 277. NATO Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 278. NATO Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 279. NATO Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 280. NATO Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 281. NATO Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 282. NATO Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. NATO Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. Global Becker Muscular Dystropy Market Size, by Country, 2017-2032 (USD Million)
TABLE 285. United States Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
TABLE 286. United States Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 287. United States Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 288. United States Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 289. United States Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 290. United States Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 291. United States Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 292. United States Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 293. United States Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 294. United States Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 295. United States Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. United States Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 297. Canada Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
TABLE 298. Canada Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 299. Canada Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 300. Canada Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 301. Canada Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 302. Canada Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 303. Canada Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 304. Canada Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 305. Canada Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 306. Canada Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 307. Canada Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. Canada Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 309. Mexico Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
TABLE 310. Mexico Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 311. Mexico Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 312. Mexico Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 313. Mexico Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 314. Mexico Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 315. Mexico Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 316. Mexico Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 317. Mexico Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 318. Mexico Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 319. Mexico Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 320. Mexico Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 321. Brazil Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
TABLE 322. Brazil Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 323. Brazil Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 324. Brazil Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 325. Brazil Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 326. Brazil Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 327. Brazil Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 328. Brazil Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 329. Brazil Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 330. Brazil Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 331. Brazil Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 332. Brazil Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 333. United Kingdom Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
TABLE 334. United Kingdom Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 335. United Kingdom Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 336. United Kingdom Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 337. United Kingdom Becker Muscular Dystropy Market Size, by Pharmacological Therapies, 2017-2032 (USD Million)
TABLE 338. United Kingdom Becker Muscular Dystropy Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 339. United Kingdom Becker Muscular Dystropy Market Size, by Therapy Approach, 2017-2032 (USD Million)
TABLE 340. United Kingdom Becker Muscular Dystropy Market Size, by Disease Modifying, 2017-2032 (USD Million)
TABLE 341. United Kingdom Becker Muscular Dystropy Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 342. United Kingdom Becker Muscular Dystropy Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 343. United Kingdom Becker Muscular Dystropy Market Size, by End User, 2017-2032 (USD Million)
TABLE 344. United Kingdom Becker Muscular Dystropy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 345. Germany Becker Muscular Dystropy Market Size, 2017-2032 (USD Million)
TABLE 346. Germany Becker Muscular Dystropy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 347. Germany Becker Muscular Dystropy Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 348. Germany Becker Muscular Dystropy Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 349. Germany B

Companies Mentioned

  • Astellas Pharma Inc.
  • BioMarin Pharmaceutical Inc.
  • Capricor Therapeutics, Inc.
  • Dyne Therapeutics, Inc.
  • Edgewise Therapeutics, Inc.
  • Epirium Bio, Inc.
  • Exonics Therapeutics, Inc.
  • Immuno Forge Co., Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Italfarmaco S.p.A.
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • ReveraGen BioPharma, Inc.
  • Roche Holding AG
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics, Inc.
  • Solid Biosciences, Inc.
  • Ultragenyx Pharmaceutical Inc
  • Wave Life Sciences Ltd.

Related Reports

Becker Muscular Dystrophy - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Becker Muscular Dystrophy - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Becker Muscular Dystrophy - Pipeline Insight, 2025 - Product Image

Becker Muscular Dystrophy - Pipeline Insight, 2025

  • Drug Pipelines
  • 40 Pages
  • Global
From
Becker Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Becker Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 134 Pages
  • Global
From
Becker Muscular Dystrophy Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035 - Product Image

Becker Muscular Dystrophy Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035

  • Report
  • Global
From
AAV Gene Therapy Drugs Market - Global Forecast 2026-2032 - Product Image

AAV Gene Therapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.